Overview
Liraglutide is a GLP-1 receptor agonist used in metabolic health protocols. GLP-1 receptor agonist.
With a half-life of ~13 hours, Liraglutide requires daily administration in most observed protocols. Administered via SubQ injection, it has a bioavailability of approximately 55% via its primary route.
Half-life approximately 13 hours. Subcutaneous bioavailability ~55%. Shorter half-life than semaglutide. Brand names: Victoza, Saxenda. One-compartment model.
Mechanism of Action
Liraglutide's pharmacological activity involves the following key pathways:
GLP-1 Receptor Activation
Liraglutide activates the glucagon-like peptide-1 (GLP-1) receptor, which is expressed in the pancreas, brain, and gastrointestinal tract.
Incretin Signaling
GLP-1 receptor activation enhances glucose-dependent insulin secretion, suppresses glucagon release, and slows gastric emptying — the incretin effect.
Dosing Protocols
The following protocols represent commonly observed dosing patterns. These are observational summaries, not recommendations.
Dose
0.6 mg/week
Route
Subcutaneous
Frequency
Once daily
Duration
8-16 weeks
Dose
3 mg/week
Route
Subcutaneous
Frequency
Once daily
Duration
8-16 weeks
Frequently Asked Questions
What is liraglutide and how does it work for weight loss?
Liraglutide is a GLP-1 receptor agonist – a synthetic analogue of the gut hormone glucagon-like peptide-1 – administered once daily via subcutaneous injection. It reduces appetite by acting on hypothalamic satiety centres, slows gastric emptying, and suppresses glucagon release, collectively reducing caloric intake. In clinical trials (SCALE programme), subjects receiving 3 mg/day lost an average of 5–8 kg more than placebo over 56 weeks.
What is the liraglutide titration schedule?
The standard titration for weight management (Saxenda) begins at 0.6 mg/day for week 1, increasing by 0.6 mg each subsequent week – reaching the target maintenance dose of 3.0 mg/day at week 5. This gradual escalation is designed to minimise gastrointestinal side effects such as nausea and vomiting. Some individuals remain at a lower dose if the full titration is not tolerated.
How long does liraglutide take to reach steady state?
Liraglutide has a plasma half-life of approximately 13 hours, meaning steady-state plasma concentrations are reached within 2–3 days of consistent daily dosing. Peak concentration occurs 8–12 hours post-injection. Full appetite-suppression and weight-loss effects typically become apparent over the first 4–8 weeks as the body adapts to the new baseline level of GLP-1 receptor activation.
What are the most common side effects of liraglutide?
The most commonly reported effects are gastrointestinal in nature – nausea, vomiting, diarrhoea, and constipation – which are most pronounced during dose escalation and tend to subside after a few weeks. Some individuals also report injection-site reactions, decreased appetite beyond the intended effect, and elevated resting heart rate. These patterns are consistent across the GLP-1 agonist class.
Can liraglutide be stacked with other peptides or compounds?
Liraglutide should not be combined with other GLP-1 receptor agonists (semaglutide, tirzepatide, retatrutide) as this produces no additive benefit and substantially increases side effect burden. It is sometimes used alongside non-GLP-1 compounds such as AOD-9604 in research contexts given their complementary fat-metabolism mechanisms, though no clinical data exists for this combination. Protein intake and resistance training are consistently recommended alongside any GLP-1 protocol to preserve lean mass.
How does liraglutide compare to semaglutide for weight loss?
Semaglutide (Ozempic / Wegovy) is a next-generation GLP-1 agonist with a much longer half-life of approximately 7 days, allowing once-weekly rather than once-daily dosing. Head-to-head and cross-trial comparisons suggest semaglutide produces roughly 2–4% greater mean body weight reduction than liraglutide at comparable timeframes. Liraglutide's shorter half-life may offer faster washout if discontinuation is needed, and its daily injection pattern allows for more granular dose adjustment.